Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Disproportionate reporting signal workbook arrived with a DSMB note on an imbalance that is not yet a signal for CMC change-control owner. That is a Pharma & Life Sciences FDA Response and Labeling decision on to drop a secondary in a labeling team facing a boxed-warning debate.

DECISION CMC change-control owner in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Disproportionate reporting signal workbook reads as Proceed under protocol once a DSMB note on an imbalance that is not yet a signal is lined up to the same Pharma & Life Sciences population. 2. Disproportionate reporting signal workbook is closer to Pause the pathway after a DSMB note on an imbalance that is not yet a signal; Proceed under protocol would over-claim this FDA Response and Labeling extract. 3. Escalate safety review is still live in disproportionate reporting signal workbook for CMC change-control owner in a labeling team facing a boxed-warning debate. 4. Disproportionate reporting signal workbook is missing the fact CMC change-control owner needs after a DSMB note on an imbalance that is not yet a signal; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 2. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal). The follow-on FDA Response and Labeling action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in disproportionate reporting signal workbook, then the action for CMC change-control owner - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Missing page in disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal, if any - Regulatory or exam hook FDA Response and Labeling would cite